The superior immune activation achieved with the nonfucosylated anti-TIGIT mAb translated into enhanced antitumor T cell responses, which may support distinctive partnerships with other therapeutic modalities, including immunotherapies that can block exhaustion of the new T cells, as well as chemotherapies, such as vedotin antibody–drug conjugate (ADC) therapies, which have been established to drive immunogenic cell death and provide new tumor-specific antigens for generation of new CD8 T cells. Here, TIGIT is linked to neoplasm.